Anti-Inflammatory Therapeutics Market by Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, and Biologics), Indication Type (Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Anti-inflammatory Bowel Disease (IBD), and Other Anti-inflammatory Diseases): Global Opportunity Analysis and Industry Forecast, 2021–2028

1.1.Report description

1.2.Key benefits for stakeholders

1.3.Key market segments

1.4.Research methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.2.Key Findings

3.2.1.Top Investment Pockets

3.2.2.Key forces shaping the anti-inflammatory therapeutics market

3.3.Market dynamics

3.3.1.Drivers

3.3.1.1.Rising incidences of autoimmune and respiratory conditions

3.3.1.2.New drug pipelines

3.3.1.3.Increasing adoption rate of anti -Inflammatory drugs

3.3.2.Restraint

3.3.2.1.side effects of anti -Inflammatory drugs

3.3.2.2.Patent expires

3.3.3.Opportunity

3.3.3.1.Developing biosimilars for the existing drugs

3.4.Market dynamics

CHAPTER 4:GLOBAL ANTI -INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.Anti- Inflammatory Biologics

4.2.1.Key market trends and opportunities

4.2.2.Market size and forecast

4.2.3.Market analysis, by country

4.3.Nonsteroidal Anti- -Inflammatory Drugs (NSAIDs)

4.3.1.Key trends and opportunities

4.3.2.Market size and forecast

4.3.3.Market analysis, by country

4.4.Corticosteroids

4.4.1.Key market trends and opportunities

4.4.2.Market size and forecast

4.4.3.Market analysis, by country

CHAPTER 5:GLOBAL ANTI-INFLAMMATORY HERAPEUTICS MARKET BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritis.

5.2.1.Market size and forecast

5.2.2.Market analysis, by country

5.3.Psoriasis

5.3.1.Market size and forecast

5.3.2.Market analysis, by country

5.4.Respiratory Diseases

5.4.1.Market size and forecast

5.4.2.Market analysis, by country

5.5.Multiple sclerosis

5.5.1.Market size and forecast

5.5.2.Market analysis, by country

5.6.Anti-Inflammatory Bowel Disease (IBD)

5.6.1.Market size and forecast

5.6.2.Market analysis, by country

5.7.Other Anti-Inflammatory disease

5.7.1.Market size and forecast

5.7.2.Market analysis, by country

CHAPTER 6:ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key trends and opportunities

6.2.2.Market size and forecast, by country

6.2.3.Market size and forecast, by drug class

6.2.4.Market size and forecast, by Indication

6.2.5.U.S.

6.2.5.1.U.S. market size and forecast, by drug class

6.2.5.2.U.S. market size and forecast, by Indication

6.2.6.Canada

6.2.6.1.Canada market size and forecast, by drug class

6.2.6.2.Canada market size and forecast, by Indication

6.2.7.Mexico

6.2.7.1.Mexico market size and forecast, by drug class

6.2.7.2.Mexico market size and forecast, by Indication

6.3.Europe

6.3.1.Key trends and opportunities

6.3.2.Europe market size and forecast, by country

6.3.3.Europe market size and forecast, by drug class

6.3.4.Europe market size and forecast, by Indication

6.3.5.Germany

6.3.5.1.Germany market size and forecast, by drug class

6.3.5.2.Germany market size and forecast, by Indication

6.3.6.UK

6.3.6.1.UK market size and forecast, by drug class

6.3.6.2.UK market size and forecast, by Indication

6.3.7.Spain

6.3.7.1.Spain market size and forecast, by drug class

6.3.7.2.Spain market size and forecast, by Indication

6.3.8.France

6.3.8.1.France market size and forecast, by drug class

6.3.8.2.France market size and forecast, by Indication

6.3.9.Italy

6.3.9.1.Italy market size and forecast, by drug class

6.3.9.2.Italy market size and forecast, by Indication

6.3.10.Rest of Europe

6.3.10.1.Rest of Europe market size and forecast, by drug class

6.3.10.2.Rest of Europe market size and forecast, by Indication

6.4.Asia-Pacific

6.4.1.Key trends and opportunities

6.4.2.Asia-Pacific market size and forecast, by country

6.4.3.Asia-Pacific market size and forecast, by drug class

6.4.4.Asia-Pacific market size and forecast, by Indication

6.4.5.Japan

6.4.5.1.Japan market size and forecast, by drug class

6.4.5.2.Japan market size and forecast, by Indication

6.4.6.China

6.4.6.1.China market size and forecast, by drug class

6.4.6.2.China market size and forecast, by Indication

6.4.7.India

6.4.7.1.India market size and forecast, by drug class

6.4.7.2.India market size and forecast, by Indication

6.4.8.Australia

6.4.8.1.Australia market size and forecast, by drug class

6.4.8.2.Australia market size and forecast, by Indication

6.4.9.South Korea

6.4.9.1.South Korea market size and forecast, by drug class

6.4.9.2.South Korea market size and forecast, by Indication

6.4.10.Rest of Asia-Pacific

6.4.10.1.Rest of Asia-Pacific market size and forecast, by drug class

6.4.10.2.Rest of Asia-Pacific market size and forecast, by Indication

6.5.LAMEA

6.5.1.Key market trends and opportunities

6.5.2.LAMEA market size and forecast, by country

6.5.3.LAMEA market size and forecast, by drug class

6.5.4.LAMEA market size and forecast, by Indication

6.5.5.Brazil

6.5.5.1.Brazil market size and forecast, by drug class

6.5.5.2.Brazil market size and forecast, by Indication

6.5.6.South Africa

6.5.6.1.South Africa market size and forecast, by drug class

6.5.6.2.South Africa market size and forecast, by Indication

6.5.7.Saudi Arabia

6.5.7.1.Saudi Arabia market size and forecast, by drug class

6.5.7.2.Saudi Arabia market size and forecast, by Indication

6.5.8.Rest of LAMEA

6.5.8.1.Rest of LAMEA market size and forecast, by drug class

6.5.8.2.Rest of LAMEA market size and forecast, by Indication

CHAPTER 7:COMPANY PROFILES

7.1.1.Company overview

7.1.2.Company snapshot

7.1.3.Operating business segments

7.1.4.Product portfolio

7.1.5.Business performance

7.1.6.Key strategic moves and developments

7.2.Amgen Inc

7.2.1.Company overview

7.2.2.Company snapshot

7.2.3.Operating business segments

7.2.4.Product Portfolio

7.2.5.Business performance

7.2.6.Key strategic moves and developments

7.3.AstraZeneca PLC.

7.3.1.Company overview

7.3.2.Company snapshot

7.3.3.Operating business segments

7.3.4.Product Portfolio

7.3.5.Business performance

7.4.Eli Lily and Company.

7.4.1.Company overview

7.4.2.Company snapshot

7.4.3.Operating business segments

7.4.4.Product portfolio

7.4.5.Business performance

7.5.F. Hoffmann-La Roche AG

7.5.1.Company overview

7.5.2.Company snapshot

7.5.3.Operating business segments

7.5.4.Product portfolio

7.5.5.Business performance

7.5.6.Key strategic moves and developments

7.6.GlaxoSmithKline plc

7.6.1.Company overview

7.6.2.Company snapshot

7.6.3.Operating business segments

7.6.4.Product portfolio

7.6.5.Business performance

7.7.Johnson & Johnson

7.7.1.Company overview

7.7.2.Company snapshot

7.7.3.Operating business segments

7.7.4.Product portfolio

7.7.5.Business performance

7.8.Merck & Co., Inc.

7.8.1.Company overview

7.8.2.Company snapshot

7.8.3.Operating business segments

7.8.4.Product portfolio

7.8.5.Business performance

7.9.Novartis AG

7.9.1.Company overview

7.9.2.Company snapshot

7.9.3.Operating business segments

7.9.4.Product portfolio

7.9.5.Business performance

7.10.PFIZER INC.

7.10.1.Company overview

7.10.2.Company snapshot

7.10.3.Operating business segments

7.10.4.Product portfolio

7.10.5.Business performance

7.10.6.Key strategic moves and developments

TABLE 01.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 02.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ANTI-INFLAMMATORY BIOLOGICS, BY REGION, 2020–2028 ($MILLION)

TABLE 03.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR NONSTEROIDAL ANTI -INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2020–2028 ($MILLION)

TABLE 04.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR CORTICOSTEROIDS, BY REGION, 2020–2028 ($MILLION)

TABLE 05.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 06.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ARTHRITIS, BY REGION, 2020–2028 ($MILLION)

TABLE 07.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR PSORIASIS, BY REGION, 2020–2028 ($MILLION)

TABLE 08.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR RESPIRATORRY DISEASE, BY REGION, 2020–2028 ($MILLION)

TABLE 09.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020–2028 ($MILLION)

TABLE 10.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR IANTI-INFLAMMATORY BOWEL DISEASE (IBD), BY REGION, 2020–2028 ($MILLION)

TABLE 11.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR OTHER IANTI-INFLAMMATORY DISEASE, BY REGION, 2020–2028 ($MILLION)

TABLE 12.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY REGION, 2020–2028 ($MILLION)

TABLE 13.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020–2028 ($MILLION)

TABLE 14.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028($MILLION)

TABLE 15.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 16.U.S. ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 17.U.S. ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 18.CANADA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 19.CANADA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 20.MEXICO ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028($MILLION)

TABLE 21.MEXICO ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 22.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020–2028 ($MILLION)

TABLE 23.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 24.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 25.GERMANY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 26.GERMANY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 27.UK ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 28.UK ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 29.SPAIN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 30.SPAIN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 31.FRANCE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 32.FRANCE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 33.ITALY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 34.ITALY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 35.REST OF EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 36.REST OF EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028($MILLION)

TABLE 37.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020–2026 ($MILLION)

TABLE 38.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 39.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 40.JAPAN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 41.JAPAN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 42.CHINA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 43.CHINA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 44.INDIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 45.INDIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 46.AUSTRALIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)

TABLE 47.AUSTRALIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 48.SOUTH KOREA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 49.SOUTH KOREA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 50.REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 51.REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 52.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020–2028 ($MILLION)

TABLE 53.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 54.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 55.BRAZIL ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 56.BRAZIL ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 57.SOUTH AFRICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 58.SOUTH AFRICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 59.SAUDI ARABIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 60.SAUDI ARABIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 61.REST OF LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)

TABLE 62.REST OF LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)

TABLE 63.ABBVIE: COMPANY SNAPSHOT

TABLE 64.ABBVIE: OPERATING SEGMENTS

TABLE 65.ABBVIE: PRODUCT PORTFOLIO

TABLE 66.AMGEN: COMPANY SNAPSHOT

TABLE 67.AMGEN: OPERATING SEGMENTS

TABLE 68.AMGEN: PRODUCT PORTFOLIO

TABLE 69.ASTRAZENECA: COMPANY SNAPSHOT

TABLE 70.ASTRAZENECA: BUSINESS SEGMENT

TABLE 71.ELI LILLY: COMPANY SNAPSHOT

TABLE 72.ELI LILLY: OPERATING SEGMENTS

TABLE 73.ELI LILLY: PRODUCT PORTFOLIO

TABLE 74.ROCHE: COMPANY SNAPSHOT

TABLE 75.ROCHE: OPERATING SEGMENTS

TABLE 76.ROCHE: PRODUCT PORTFOLIO

TABLE 77.GLAXOSMITHKLINE: COMPANY SNAPSHOT

TABLE 78.GLAXOSMITHKLINE: OPERATING SEGMENTS

TABLE 79.GLAXOSMITHKLINE: PRODUCT PORTFOLIO

TABLE 80.JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 81.JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 82.JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 83.MERCK: COMPANY SNAPSHOT

TABLE 84.MERCK: OPERATING SEGMENTS

TABLE 85.MERCK: PRODUCT PORTFOLIO

TABLE 86.NOVARTIS: COMPANY SNAPSHOT

TABLE 87.NOVARTIS: OPERATING SEGMENTS

TABLE 88.NOVARTIS: PRODUCT PORTFOLIO

TABLE 89.PFIZER: COMPANY SNAPSHOT

TABLE 90.PFIZER: OPERATING SEGMENTS

TABLE 91.PFIZER: PRODUCT PORTFOLIO